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Influenza is the seventh leading cause of death 
in the United States (Beigel, 2008), with the el-
derly,  the  very  young,  pregnant  women,  and 
otherwise  immune-compromised  populations 
accounting for >90% of influenza-related deaths. 
The pandemic H1N1 influenza virus strain is 
immunologically distinct from other influenza 
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The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of 
reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and 
monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike 
antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced 
by pandemic H1N1 infection were broadly cross-reactive against epitopes in the hemagglu-
tinin (HA) stalk and head domain of multiple influenza strains. The antibodies were from 
cells that had undergone extensive affinity maturation. Based on these observations, we 
postulate that the plasmablasts producing these broadly neutralizing antibodies were 
predominantly derived from activated memory B cells specific for epitopes conserved in 
several influenza strains. Consequently, most neutralizing antibodies were broadly reactive 
against divergent H1N1 and H5N1 influenza strains. This suggests that a pan-influenza 
vaccine may be possible, given the right immunogen. Antibodies generated potently pro-
tected and rescued mice from lethal challenge with pandemic H1N1 or antigenically dis-
tinct influenza strains, making them excellent therapeutic candidates.
© 2011 Wrammert et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
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viruses, leaving large population groups sus-
ceptible to infection (Brockwell-Staats et al., 
2009; Dawood et al., 2009; Garten et al., 2009; 
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most other H1N1 and H5N1 influenza strains, especially in 
high-risk populations such as immunosuppressed patients and 
the elderly.
RESULTS
Influenza-specific plasmablasts are persistently induced 
throughout infection, providing a rich source of antiviral mAbs
B cell responses were examined in nine patients infected with 
the pandemic 2009 H1N1 influenza virus. These patients had 
varying courses and severity of disease. The cases ranged from 
mild disease with rapid viral clearance within a few days after 
onset of symptoms to severe cases that shed virus for several 
weeks and required hospitalization with ventilator support.   
A majority of the patients were treated with antiviral drugs. 
The diagnoses were confirmed by pandemic H1N1-specific 
RT-PCR and serology. All patients had neutralizing titers of 
serum antibodies at the time of blood collection. A summary 
of the clinical patient data are shown in Table I. The majority 
of samples were obtained around 10 d after the onset of symp-
toms, with the exception of a particularly severe case where 
sampling was done 31 d after symptom onset.
Antigen-specific plasmablasts appear transiently in periph-
eral blood after vaccination with influenza or other vaccines 
(Brokstad et al., 1995; Bernasconi et al., 2002; Sasaki et al., 2007; 
Wrammert et al., 2008), but the kinetics of their appearance and 
persistence during an ongoing infection remain unclear. Here, 
we have analyzed the magnitude and specificity of the plasma-
blast response in blood samples taken within weeks after onset of 
clinical symptoms of pandemic H1N1 influenza virus infection. 
Using a virus-specific ELISPOT assay, it was possible to show a 
significant number of pandemic H1N1-reactive plasmablasts in 
the blood of the infected patients, whereas none were detectable 
in a cohort of healthy volunteers (Fig. 1, A and B). These cells 
were also readily detectable several weeks after symptom onset in 
the more severe cases. Fig. 1 (A and C) illustrates that, of the total 
IgG-secreting cells, over half of the cells were producing anti-
bodies that bound pandemic H1N1 influenza virus. Moreover, 
plasmablasts specific for HA occurred at 30–50% the frequency 
of virus-specific cells (Fig. 1, C and D), the specificity most likely 
to be critical for protection. Most patients also had a relatively 
high frequency of plasmablasts, forming antibodies that bound 
to past, seasonal influenza strains (Fig. 1 C) or recombinant HA 
from the previous annual H1N1 strain, A/Brisbane/59/2007. 
Based on the overall frequency of pandemic H1N1-specific 
cells, it is likely that the cells binding other strains were overlap-
ping populations and cross-reactive. None of the induced plas-
mablast cells bound to recombinant HA from the H3N2 strain 
from the same vaccine (A/Brisbane/10/2007). These findings 
demonstrate that influenza-specific human plasmablasts are con-
tinuously generated throughout an ongoing infection and that a 
fairly high proportion of these cells make antibodies that also 
cross-react with previous annual H1N1 influenza strains.
To analyze the specificity, breadth, and neutralizing capacity 
of these plasmablasts, we used single-cell PCR to amplify the 
heavy and light chain variable region genes from individually 
Hancock  et  al.,  2009). The  Centers  for  Disease  Control   
reports  that  there  were  an  estimated  60  million  cases  of   
the 2009 H1N1 pandemic strain, which caused 256,000 
hospitalizations. An unusually high frequency of severe dis-
ease  occurred  in  younger  and  otherwise  healthy  patients 
(Hancock et al., 2009). In addition, rare infections with avian   
H5N1 influenza strains in humans had close to a 50% mor-
tality rate (Subbarao and Joseph, 2007). Emergence of a   
zoonotic or antigenically distinct strain that combined even   
a fraction of the morbidity and mortality of the pandemic 
H1N1 and H5N1 viruses would have dire consequences. 
Antibodies play a key role in protection against influenza in-
fection in vivo (Puck et al., 1980; Gerhard et al., 1997; Luke 
et al., 2006; Simmons et al., 2007). The fact that there were 
little  or  no  preexisting  antibody  titers  present  before  the 
emergence of this pandemic virus, and that the virus atypi-
cally caused such severe disease in young adult, illustrates the 
importance  of  comprehensively  understanding  the  B  cell   
responses  and  antibody  specificities  induced  by  infection 
with this influenza virus.
Here, we have analyzed the plasmablast responses induced 
by pandemic H1N1 infection and generated a panel of mono-
clonal antibodies (mAbs) from these cells to analyze their char-
acteristics in detail. In contrast to seasonal vaccination, we show 
that a majority of the neutralizing antibodies induced by infec-
tion were broadly cross-reactive with all recent annual H1N1 
strains, as well as the highly pathogenic 1918 H1N1 and avian 
H5N1 strains. These neutralizing antibodies bound predomi-
nantly to conserved epitopes in the hemagglutinin (HA) stalk 
region (Ekiert et al., 2009; Sui et al., 2009), with some binding 
to novel epitopes in the HA globular head. The high frequency 
of these HA-stalk binding antibodies is of particular interest, as 
this epitope is a promising target for a broadly protective influ-
enza vaccine (Steel et al., 2010). Furthermore, the cross-reactive 
antibodies carried highly mutated immunoglobulin genes, in-
dicative of extensive affinity maturation. Together, these find-
ings support a model in which infection predominantly activated 
broadly cross-reactive memory B cells that then underwent fur-
ther affinity maturation. We propose that the expansion of these 
rare types of memory B cells may explain why most people did 
not become severely ill, even in the absence of preexisting pro-
tective antibody titers. Recent studies in mice strongly support 
the idea that consecutive immunizations with antigens from 
divergent influenza stains can indeed hone the antibody re-
sponse to preferentially target broadly protective conserved 
epitopes (Wang et al., 2010; Wei et al., 2010). Our findings 
demonstrate that cross-reactive antibodies can be preferen-
tially induced in humans given the right immunogen, pro-
viding further support for the feasibility of generating a 
pan-influenza vaccine. Finally, in vivo challenge experiments 
showed that the neutralizing antibodies isolated protected mice 
challenged with a lethal dose of pandemic H1N1 influenza   
virus, even when administered therapeutically 72 h after 
infection, and also provided protection against antigenically 
distinct H1N1 influenza strains. These antibodies are thus 
promising as therapeutics against pandemic H1N1, as well as JEM VOL. 208, January 17, 2011 
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activated by pandemic H1N1 infection. Consistent with the 
frequency of plasmablasts secreting antibodies binding annual 
influenza strains by ELISPOT analyses (Fig. 1 C), a majority 
(29/46, or 63%) of the pandemic H1N1-specific antibodies 
also cross-reacted with seasonal influenza viruses (Fig. 2,   
A and B). In fact, by ELISA, one third of these antibodies bind 
to the prepandemic strains at lower concentrations than they 
did to the pandemic H1N1 strain, suggesting higher avidity 
binding. By comparison, only 22% (11/50) of plasmablasts 
induced by annual H1N1 strains before the pandemic could 
bind the pandemic H1N1 influenza (Fig. S1 B). We propose 
that  the  cross-reactivity  of  pandemic  H1N1-induced  cells   
derives from the activation of memory cells originally specific 
for past influenza immunizations in an original antigenic   
sin fashion.
Evidence of extensive affinity maturation suggests a high 
frequency of memory cell activation against the pandemic 
H1N1 strain
Based on the 10–15-fold induction of plasmablasts and ex-
pression of intracellular Ki67 during ongoing immune re-
sponses (Brokstad et al., 1995; Bernasconi et al., 2002; Sasaki 
et al., 2007; Smith et al., 2009; Wrammert et al., 2008), we can 
assume that most plasmablasts result from the ongoing infection 
sorted cells (defined as CD19+, CD20lo/, CD3, CD38high, 
CD27high cells; Fig. 1 E; Wrammert et al., 2008; Smith et al., 
2009). These genes were cloned and expressed as mAbs in 293 
cells, and the antibodies were screened for reactivity by ELISA. 
Thresholds for scoring antibodies as specific to the influenza an-
tigens were empirically determined based on being two standard 
deviations greater than the background level of binding evident 
from 48 naive B cell antibodies (Fig. S1 A). Of 86 antibodies 
generated in this fashion, 46 (53%) bound pandemic H1N1   
(Fig. 1 F) and one third (15 antibodies) were reactive to HA 
(Fig. 1 G and Fig. S2 A), most of them at sub-nanomolar avidities 
(based on surface plasmon resonance analyses; Fig. S2 B). On a 
per donor basis, 55% of the mAbs bound to purified pandemic 
H1N1 virions (range: 33 to 77%). Of the virus-specific anti-
bodies, 31% bound to recombinant HA (range: 14 to 55%). We 
conclude that virus-specific plasmablasts are readily detected after 
pandemic H1N1 influenza virus infection and that virus-specific 
human mAbs can be efficiently generated from these cells.
Plasmablasts from patients infected with pandemic H1N1 
influenza were highly cross-reactive to prepandemic 
influenza strains
As the plasmablasts are specifically induced by the ongoing 
immune response, we can learn about the origin of the B cells 
Table I.  Summary of clinical data for patients with acute pandemic H1N1 virus infections
Patient Age Gender HAI 
titer
MN 
titer
Co-
morbidities
Initial symptoms Hospital course Sample 
collection
Antiviral 
treatment
mAb
EM 30 F 640 1280 none Fever, cough, dyspnea Acute respiratory distress syndrome, 
bacterial pneumonia, pulmonary 
embolism, prolonged oscillatory 
ventilator support, tracheostomy, 
discharged after 2 mo
Day 31 Oseltamivir Yes
1000 37 M 80 40 Hypertension, 
interstitial 
lung disease 
of unknown 
etiology
Fever, cough, shortness 
of breadth, nausea, 
vomiting
Pneumonia, acute sinusitis, acute renal 
failure, discharged after 8 d
Day 18 Oseltamivir, 
Zanamavir
Yes
70 38 F 80 160 none Fever, cough, body aches N/A Day 15 None Yes
1009 21 M 20 20 Congenital 
heart disease, 
repair for 
Tetralogy of 
Fallot
Fever, cough, sore throat, 
nausea, diarrhea
N/A Day 9 Oseltamivir Yes
1010 24 M 10 10 none Fever, cough, nausea, 
vomiting diarrhea
N/A Day 11 Oseltamivir No
1011 25 M 20 10 none Fever, cough, sore throat, 
vomiting, headache, 
confusion
N/A Day 9 Oseltamivir No
1013 26 M 80 160 none Fever, cough, sore throat, 
body aches, nausea, 
vomiting, diarrhea
N/A Day 9 None No
1014 45 F 80 20 none Fever, chills, cough, 
sore throat, body aches, 
headache, nausea, 
vomiting
N/A Day 9 None No
The mAb column indicates whether mAbs were made from the plasmablasts of these patients.184 Human B cell responses to pandemic H1N1 influenza | Wrammert et al.
Figure 1.  Generation of human mAbs against pandemic H1N1 influenza virus from infected patients. (A and B) Magnitude of the plasmablast 
response observed in peripheral blood of six pandemic H1N1-infected patients and 22 healthy (noninfected/nonvaccinated) donors by ELISPOT analysis. 
(A) Representative ELISPOT. Numbers of plasmablasts secreting antibody reactive to pandemic H1N1 is compared with the total number of IgG-secreting 
cells from each PBMC sample (numerals). All ELISPOT assays were performed in duplicate. (B) Summary of all the donors analyzed; each dot represents 
one patient or control. (C and D) Specificity of the sorted plasmablasts measured by ELISPOT analysis. Representative ELISPOT showing plasmablasts pro-
ducing antibodies reactive with total IgG or pandemic H1N1 whole virus, annual influenza vaccine (2009/2010 TIV vaccine), or recombinant HA from pan-
demic H1N1, the previous year’s annual vaccine H1N1 strain (A/Brisbane/59/2007), or the previous years H3N2 strain (A/Brisbane/10/2007). (D) Summary 
of the frequency of whole IgG secreting cells specific to pandemic H1N1 whole virus, recombinant HA from pandemic H1N1, and recombinant HA from the 
previous year’s vaccine. Donors EM1 and SF1000 were not analyzed in this fashion, as the antigens were not available for live-cell analyses at that time point 
in the pandemic. (E) Sorting of plasmablast cells from pandemic H1N1 influenza–infected patients to generate mAbs. Flow cytometry plots show the per-
centage of CD27hiCD38hi cells (dot plots are gated on CD3CD20lo/ lymphocytes). The plasmablasts are defined herein as CD3CD20lo/CD19+CD38hiCD27hi cells. 
(right) An example of post-sort purity of ungated cells (verified for each sample). Single plasmablasts were isolated from the sorted fraction by cell sorting, 
and variable antibody genes were cloned from individual cells (see Materials and methods). (F and G) Scatchard plots of binding of the isolated mAbs to 
pandemic H1N1 whole-purified virus (F) and pandemic H1N1 recombinant HA (G) as measured by ELISA. Antibodies were scored positive (frequency above 
plots) if they bound at least two standard deviations greater than the mean absorbance of naive B cell antibodies at 10 µg/ml (detailed in Fig. S1 A).  JEM VOL. 208, January 17, 2011 
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(averaging >19 per patient; Fig. 2 D and Fig. S3 A). For these 
5 patients, mutations had accumulated significantly more than 
from primary IgG plasmablast responses to anthrax or vac-
cinia (small pox) vaccines, and more so than for IgG-positive 
memory B cells from our historical data that averaged 14/VH 
gene (Student’s t test P < 0.05; Zheng et al., 2004, 2005; Koelsch 
et al., 2007; Wrammert et al., 2008; Fig. 2 C and Fig. S3 B) or 
from 347 IgG memory cell sequences previously published 
by another group (averaging 15/VH gene; de Wildt et al., 
2000). Interestingly, for patient EM (outlier in Fig. 2 D) who 
had the most severe infection (Table I), mutations had accu-
mulated at a significantly lower frequency than the IgG con-
trols (Fig. S3 A; P < 0.0001), suggesting a unique circumstance 
such as a low-level or lacking primary response. Detailed se-
quence characteristics for pandemic H1N1-induced plasma-
blasts are provided in Tables S1–S3. Though based on a limited 
or vaccine response. The ready detection of clonal expansions 
at a mean frequency of 16.5% of the cells for the six patients 
supports this view (based on CDR3 sequence similarity;   
Fig. 2 C). Since the discovery of somatic mutation, it has been 
appreciated that mutations progressively accumulate on vari-
able genes after repeated immunizations (McKean et al., 
1984). Thus, we can gain insight into the origin of the pan-
demic H1N1 response by comparing the somatic mutation 
frequency of the plasmablasts present during H1N1 infection 
to that of other plasmablast responses. The PCR strategy al-
lowed isolation of either IgG or IgA transcripts and identified 
68% IgG and 32% IgA plasmablasts from the patients. Similar 
to plasmablasts induced by annual vaccination (Wrammert   
et al., 2008), or after a fourth booster vaccine to anthrax, the 
variable genes of novel H1N1-induced cells from five of the 
six patients harbored high numbers of somatic mutations   
Antibodies were tested at 10 µg/ml and threefold serial dilutions until a nonbinding concentration was determined. Each antibody was tested in at least 
two (and typically more) replicates for specificity and affinity estimations. Note that only 14 of 15 HA-binding antibodies have curves in G because one of 
the HA-reactive antibodies only binds HA on whole virions, not on the recombinant protein.
 
Figure 2.  Plasmablasts induced by  
pandemic H1N1 infection are highly 
cross-reactive and have accumulated  
particularly high levels of variable gene 
somatic hypermutation. (A and B) Pandemic 
H1N1 reactive mAbs isolated from infected 
patients (1000, EM, 70, 1009) were assayed for 
binding to annual H1N1 influenza strain 
whole virus. The minimum detectable concen-
tration is defined as two standard deviations 
above the mean binding of 48 randomly cho-
sen naive B cell antibodies (Fig. S1 A). Bars are 
color coded to approximate levels of cross-
reactivity to the annual vaccine (circulating) 
strains of recent years. Panels A and B use the 
same color scheme. Each value is representa-
tive of at least two replicate ELISAs repeated 
until a single consistent minimum concentra-
tion was established. The center numeral 
equals total antibodies. (C) Analysis of the 
variable gene sequences from plasmablasts of 
the four pandemic H1N1-infected patients 
indicated that 16.5% of the pandemic 
H1N1-induced plasmablasts were clonally 
related (shared identical VH and JH genes and 
CDR3 junctions). (D) The average number of 
somatic hypermutations in the pandemic 
H1N1 patient plasmablast variable region 
genes compared with primary IgG plasmablast responses to vaccinia (small pox) or the anthrax vaccine, or after at least 4 boosters with the anthrax vac-
cine. To account for the obvious outlier in the pandemic H1N1 group (patient-EM), median values are indicated by the bar. Student’s t tests excluding the 
outlier indicated a p-value of <0.04 for the remaining five pandemic H1N1 samples compared with the IgG memory and germinal center (GC) cells or the 
primary IgG plasmablast responses (0.2 with EM included) and a p-value of <0.0001 against the IgM populations. Notably, besides patient EM, each indi-
vidual set of VH genes averaged significantly more mutations than the IgG memory and GC or the primary responses (Fig. S3 A). Each point represents 
one individual donor and is averaged from 25–75 sequences, except for the primary response to anthrax from which only 10 VH genes could be cloned 
from single cells because of the highly limited response. Mutations accumulated per individual sequence are depicted in Fig. S3. Detailed sequence char-
acteristics are provided in Tables S1–S3. The naive, IgG and IgM GC and memory populations are derived from historical data (Zheng et al., 2004, 2005; 
Koelsch et al., 2007; Wrammert et al., 2008).186 Human B cell responses to pandemic H1N1 influenza | Wrammert et al.
indicating that they bound to sites other than the HA active 
site. Interestingly, antibodies of the latter type were predomi-
nant in the response (Fig. 3 A). This specificity is reminiscent 
of antibodies against the recently discovered broadly neutral-
izing epitopes found on the HA stalk, rather than those lo-
cated on the HA globular head that is more typical for 
neutralizing antibodies (Ekiert et al., 2009; Sui et al., 2009). 
Importantly,  five  of  these  antibodies  are  indeed  of  similar 
specificity  (including  antibodies  70-5B03,  70-1F02,  1000-
3D04, and a clonal pair from donor 1009: 3B05 and 3E06). 
These five antibodies bind with high affinity to most H1 
strains including all from the vaccines of the past 10 yr, the 
1918 pandemic strain, and to the H5 of a highly pathogenic 
number  of  patients,  the  frequent  cross-reactivity  and  high 
number of somatic mutations support a model in which many 
of the plasmablasts induced by pandemic H1N1 infection 
arose from cross-reacting memory B cells.
A majority of the neutralizing antibodies bound to highly 
conserved epitopes in both the HA stalk and head regions
A high frequency of the HA-specific antibodies was able to 
neutralize the virus in vitro (totaling 73% or 11/15; Fig. 3 A). 
These neutralizing antibodies could be further categorized 
into two distinct groups: (a) neutralizing antibodies that 
displayed hemagglutination inhibition (HAI) activity (HAI+) 
and (b) neutralizing antibodies that had no HAI activity,   
Figure 3.  HA-specific antibodies induced by pandemic H1N1 infection bind cross-reactive neutralizing epitopes. (A) In vitro functional analysis 
of 15 antibodies from indicated patients that bound pandemic H1N1 influenza recombinant HA protein. The left panel shows HAI minimum effective 
antibody concentration, the middle panel shows PRNT50 plaque reduction neutralization minimum effective antibody concentration, and the right panel 
shows ELISA binding summarized as minimum positive concentration (as defined for Fig. 2) against recombinant HA (original curves are in Fig. 1 F and 
Fig. S2 A). The antibodies are grouped based on whether they show HAI and/or neutralizing (neut) function. Antibody 1009-3B06 was only tested for 
binding to whole virus, as this antibody did not bind to rHA due to binding of a quaternary or conformationally sensitive epitope that is not present in the 
recombinant protein. HAI and neutralization assays were performed in duplicate and repeated at least three times. ELISA curves are provided in Fig. S2 A. 
(B) ELISA binding as shown by minimum positive concentration (defined for Fig. 2) of neutralizing mAbs to rHA or whole virions from pandemic H1N1 or 
other influenza strains (ELISA binding curves are provided in Fig. S2 A). Three binding patterns (epitopes 1 and 2, and 3) were observed that coincided  
with specificity comparisons by competitive ELISA, as illustrated in Fig. 4 A. (C) Three representative neutralizing antibodies (EM-4C04, 70-1F02, and  
1009-3B06) were used for HAI and microneutralization (MN) activity against pandemic H1N1 and several other annual or laboratory H1N1 influenza 
strains. Experiments were performed in duplicates and repeated at least three times. Minimum effective concentration is shown for both assays.JEM VOL. 208, January 17, 2011 
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FACS analysis showed that the five antibodies bound to all 13   
H5 variants tested at levels quite similar to F10, for which a crys-
tal structure had been generated to define this epitope. Thus,   
half of the neutralizing and a surprising 10% of all antibodies 
induced by pandemic H1N1 infection bound to a conserved, 
critical epitope on the HA stalk. By comparison, none of   
50 H1N1 strain-specific antibodies that we had previously 
isolated after annual vaccination before the 2009 pandemic 
had this reactivity (unpublished data). The frequency of 
pandemic-induced, stem-reactive antibodies (5/46) versus those 
from annual vaccine (0/50) is significantly greater (Chi-square 
test, P = 0.02). Further, this specificity is only rarely seen in 
human memory B cells (Corti et al., 2010) or from phage-
display libraries (Sui et al., 2009). These observations support 
avian influenza strain (Fig. 3 B and Fig. S2 A). In addition, 
these five antibodies cross-compete for a similar epitope that 
was not over-lapping with the HAI+ antibodies (Fig. 4 A, 
epitope-1). These antibodies are competitively inhibited by a 
commercial antibody referred to as C179 that binds this HA 
stalk region (Okuno et al., 1993), and four of five of these 
antibodies are encoded by the hallmark VH1-69 gene (Ekiert   
et al., 2009; Sui et al., 2009). To verify HA stalk reactivity, 
these five antibodies were tested for binding to H5 variants 
predicted to affect the stalk epitope by the crystal structure, 
and their binding patterns were compared with that of the 
prototypical  stalk  antibody  (mAb  F10;  Sui  et  al.,  2009;   
Fig. 4 B). Each H5 variant has a single residue mutation in 
the stalk region and was transiently expressed on 293T cells. 
Figure 4.  The neutralizing antibodies bind to three nonoverlapping epitopes in either the stalk or the globular head of the HA molecule.  
(A) Competition ELISA assays were used to determine the similarity in specificity between the various neutralizing antibodies. Shown is the percentage of 
competition of each antibody in an ELISA binding assay against all other neutralizing antibodies. A 10-fold molar excess of unlabeled antibody was used 
to inhibit a biotinylated antibody. Percent competition is calculated as the reduction in absorbance relative to the level of inhibition of any particular anti-
body against itself. Colors indicate degree of inhibition of antibody binding, as indicated. Antibody C179 is a commercial antibody that binds to the stalk 
region of the HA molecule identifying epitope-1. Epitope-2 and -3 are each on the HA-head active site. 1000-2G06 and the nonneutralizing, but HA-
binding, antibodies had no competition with any of the other HA-reactive antibodies and are therefore not shown. VH gene usage of the individual anti-
bodies is listed on the right. All assays were performed in duplicate. (B) Plasmids encoding full-length WT H5-TH04 (A/Thailand/2-SP-33/2004 [H5N1]) and 
its mutants were transiently transfected into 293T cells. 24 h after transfection, cells were harvested for FACS analysis, and binding of indicated antibodies 
was tested at 10 µg/ml. The cell surface HA expression of each of the mutants were verified with a ferret anti-H5N1 serum (not depicted). Antibody F10 
was one of the antibodies used to characterize the HA stalk epitope by x-ray crystallography (Sui et al., 2009) and served as a positive control for the 
binding pattern expected of HA stalk–reactive antibodies to these HA mutants.188 Human B cell responses to pandemic H1N1 influenza | Wrammert et al.
to all recent H1 vaccine strains and reacted strongly to the 
1918 pandemic strain (antibodies 1009-3E04 and 1000-3E01; 
Fig. 3 B and Fig. 4 A, epitope-3). These mAbs bind to past 
vaccine strains with higher avidity than to the pandemic H1N1. 
Further studies are underway to precisely identify the epitopes 
of all neutralizing antibodies in this study.
Only two of 11 neutralizing antibodies were highly specific 
for the pandemic H1N1 strain alone (Fig. 3 B and Fig. S2 A), in-
cluding a low avidity antibody, 1000-2G06, which only showed 
slight neutralization capacity in vitro, and EM-4C04, which 
was very effective at neutralizing the pandemic H1N1 influ-
enza. We conclude from these experiments that a surprising 
82% (9/11) of the neutralizing plasmablasts that we isolated 
during pandemic H1N1 influenza infections were broadly 
cross-reactive to multiple influenza strains.
Potent in vivo protection and rescue of mice challenged 
with a lethal dose of pandemic H1N1 or antigenically 
distinct influenza virus strains
There is a distinct interest in developing monoclonal anti-
bodies for use in a therapeutic setting. We selected three rep-
resentative antibodies of the set we have identified for detailed 
functional analysis both in vitro (Fig. 3 C) and in vivo (Fig. 5 
and Fig. 6), including: EM-4C04, 1009-3B06, and 70-1F02. 
 The antibodies EM-4C04 and 1009-3B06 are specific for the 
active site of the HA molecule, whereas 70-1F02 binds to the 
stalk region. Furthermore, EM-4C04 is highly specific for 
pandemic  H1N1,  whereas  1009-3B06  and  70-F02  display 
the idea that a vaccine might be developed that preferentially 
targets the HA stalk, thus providing broad protection against 
many influenza strains.
The remaining neutralizing antibodies were HAI+ and 
therefore bound to the HA globular head. Based on cross-
competition analyses, these antibodies fell into two groups 
binding nonoverlapping regions of the HA head, including 
epitope-2 and epitope-3 (Fig. 3 B and Fig. 4 A). Indeed, using 
spontaneous escape mutant selection, we found that the 
EM4C04 mAb binds to the Sa region of the HA globular 
head (unpublished data). Thus, by proximity based on the 
competition assay (Fig. 4 A), we can predict that all of the   
epitope-2 antibodies bind near the Sa/Sb region (including 
EM-4C04, 1009-3B06, and 1009-3F01).
Broadly reactive antibodies binding both pandemic H1N1 
strains and common annual H1N1 strains have been identi-
fied both in humans (Krause et al. 2010; Xu et al., 2010) and 
in mice (Manicassamy et al., 2010). It is notable that three of 
five of the HA globular-head–binding antibodies induced by 
pandemic H1N1 infection were also broadly reactive to vari-
ous H1N1 strains (Fig. 3 B). One such novel antibody was the 
SF1009-3B06  antibody  that  reacts  strongly  with  the  pan-
demic H1N1 strain, as well as all recent H1N1 vaccine strains 
(Fig. 3 B and Fig. S2 A). The precise epitope to which the 
1009-3B06 antibody binds appears to be quite unique; it is 
only accessible on whole virions, not on recombinant HA, 
suggesting that the epitope is quaternary in nature. Finally, 
two antibodies cross-reacted and inhibited hemagglutination 
Figure 5.  In vivo prophylactic and thera-
peutic efficacy of human mAbs against 
pandemic H1N1 influenza virus. 6–8-wk-
old BALB/c mice were infected with a 3xLD50 
dose of highly pathogenic, mouse-adapted 
2009 pandemic H1N1 influenza (A/California/ 
04/09). 24, 48, and 60 h after infection,  
200 µg (10 mg/kg of body weight) of EM-
4C04, 70-F02, or 1009-3B06 human mAb 
were injected intraperitoneally. All mice were 
monitored daily for body weight changes and 
any signs of morbidity and mortality. Percent-
age of initial body weight is plotted, and the 
number of surviving mice is shown in the 
lower right of each plot. Infected, untreated 
mice showed clear signs of sickness around 
day 4–5 after infection and perished by day 
8–9. Prophylactic treatment is shown on the 
left for comparison. Antibody treatment con-
ferred significant protection as determined by 
comparison of weights in untreated versus 
prophylaxis and at the time of treatment  
versus 12 d after infection (unpaired, two-
tailed Student’s t test, P < 0.05). The log-rank 
test indicated significant survival as well  
(P < 0.001). Figure shows one representative 
experiments of at least three independent 
repeat experiments.JEM VOL. 208, January 17, 2011 
Article
189
for the pandemic H1N1, had no protective effect on infection 
with PR/8/34 or FM/1/47. In conclusion, the antibodies 
characterized herein show promise for development as broadly 
reactive therapeutic agents against the pandemic H1N1 influ-
enza virus, as well as against the majority of H1N1 and H5N1 
influenza strains.
DISCUSSION
Our findings provide insight into the human B cell responses 
to  a  pandemic  influenza  virus  strain. The  unique  genetic 
composition of the pandemic H1N1 influenza virus meant 
that our relatively young cohort probably had little or no pre-
existing specific antibody-mediated immunity to this virus 
before infection (Brockwell-Staats et al., 2009; Dawood et al., 
2009; Garten et al., 2009; Hancock et al., 2009). Thus, two 
sources of B cells could have contributed to this response: 
newly recruited naive B cells and preexisting memory B cells 
that bound to epitopes conserved between past seasonal 
strains and the pandemic H1N1 strain. We theorize that pre-
dominant activation of the latter, preexisting memory cells 
can account for the observed high frequency of neutralizing 
antibodies  (11/15  HA-binding  antibodies),  the  majority 
(9/11) of which are cross-reactive with seasonal H1N1 strains 
(Fig. 3 C) and other group 1 influenza strains, including H5 HA. 
Several observations support this conjecture.
Most convincingly, there was a particularly high frequency 
of cross-reactive antibodies overall, with a high level of so-
matic mutations found particularly among the variable genes 
of cross-reacting cells (Fig. 2 and Fig. S3). In fact, by ELISA 
most antibodies were cross-reactive and one third of the   
broadly cross-reactive binding (Fig. 3 B) and have functional 
activity against multiple recent and older H1N1 strains (Fig. 3 C). 
These antibodies were all highly effective at providing pro-
phylactic protection against infection with a lethal dose of 
mouse-adapted pandemic H1N1 in 6–8-wk-old BALB/c mice 
(Fig. 5). Moreover, all three antibodies were effective thera-
peutically, even when they were administered as late as 60 h 
after the lethal challenge infection, well after the mice were 
symptomatic. For EM-4C04, we have successfully treated mice 
as far out as 72 h post-infection (unpublished data). Infected 
mice were already showing measurable weight loss that was 
reversed  by  administration  of  the  antibody,  demonstrating 
therapeutic potential even after the onset of disease. Viral 
clearance was analyzed in mice treated at 48 h after infection 
with EM4C04 (Fig. S4). As early as day 4, the antibody-treated 
mice exhibited more than a log reduction in viral titers; titers 
continued to decline, such that by day 6, virus was undetect-
able or present at very low levels. The untreated mice per-
ished by day 7 or 8, whereas the treated mice cleared the 
infection with no detectable virus on day 12. Finally, 1009-
3B06  and  70-1F02,  which  showed  activity  against  several 
current and older H1N1 seasonal influenza strains in vitro 
(Fig. 3 C), were also tested in vivo against antigenically dis-
tinct influenza strains. For these experiments, mice were 
treated with 200 µg of mAb intraperitoneally 12 h before in-
fection with a lethal dose of either pandemic H1N1 influenza 
or either of the two common influenza laboratory strains 
PR/8/34  or  FM/1/47.  1009-3B06  and  70-1F02  showed 
protection against these antigenically distinct H1N1 influenza 
strains, as illustrated in Fig. 5. EM-4C04, which is highly specific   
Figure 6.  Breadth of in vivo prophylactic 
efficacy in mice. 6–8-wk-old BALB/c mice 
were treated with 200 µg (10 mg/kg of body 
weight) EM-4C04, 70-1F02, or 1009-3B06 
human mAb intraperitoneally. Control mice 
were treated with PBS only, a control mAb or 
polyclonal human IgG. 12 h later, they were 
challenged with a 3xLD50 dose of mouse 
adapted pandemic H1N1, PR/8/34, or FM/1/47 
influenza virus. All mice were monitored daily 
for body weight changes and any signs of 
morbidity and mortality. Percentage of initial 
body weight (left) and survival curves (right) 
are plotted. Infected, untreated mice showed 
clear signs of sickness 4–5 d after infection 
and perished by day 8–9. Figure shows one 
representative experiments of at least three 
independent repeat experiments. Antibody 
treatment conferred significant protection as 
determined by comparison of weights in un-
treated versus prophylaxis, and at the time of 
treatment versus 12 d after infection (un-
paired, two-tailed Student’s t test, P < 0.05). 
The log-rank test indicated significant survival 
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seroconversion, or by the presence of highly potent antibodies, 
such as EM-4C04, whose activities were less likely to titer 
out. The highly specific nature of the response from this pa-
tient may have contributed to this advantage, ultimately better 
targeting the epitopes of the pandemic H1N1 strain. In con-
trast, patient 1009 had relatively low HAI and MN serum titers 
but the highest frequency of broadly neutralizing antibodies 
and a less severe disease course. One possibility is that our 
sampling from this patient was done before peak serological 
responses. Another possibility is that the high frequency of 
these potent antibodies in the memory B cell compartment 
may have resulted in rapid resolution of infection, precluding 
the development of a high serological response. A third possi-
bility is that despite broader protection, the stalk-reactive anti-
bodies are on the whole less potent and more rapidly titrated 
out than the highly specific antibodies to the HA globular 
head. These various possibilities will be of significant interest 
to study in the future.
Finally, we report the development of a large panel of   
human mAbs induced by pandemic H1N1 infection. Pro-
phylactic therapy with polyclonal or mAbs has successfully 
been used for RSV, rabies, Hepatitis A and B, and varicella.   
In the case of influenza, mAbs have been shown to provide 
prophylactic or therapeutic protection in mice and other ani-
mal models (Reuman et al., 1983; Sweet et al., 1987; Palladino 
et al., 1995; Renegar et al., 2004). Passive transfer of maternal 
antibodies in humans has also been shown to confer protec-
tion (Puck et al., 1980). Several of the antibodies we isolated 
have broad neutralization capacity in vitro against divergent 
influenza strains and show potent prophylactic and therapeu-
tic activity when used to treat mice that were lethally infected 
with influenza. These antibodies could provide much needed 
pandemic therapeutics to treat severe cases of influenza and to 
protect high-risk populations.
In conclusion, analyses of the 46 mAbs induced by pan-
demic H1N1 infection indicated frequent activation of broadly 
reactive B cells. We propose that these cells had a memory cell 
origin caused by cross-reactivity to conserved and function-
ally important epitopes. If true, it will be important to char-
acterize the efficacy of the pandemic H1N1 vaccine to induce 
a similarly cross-protective response.
MATERIALS AND METHODS
Patients. All studies were approved by the Emory University, University of 
Chicago,  and  Columbia  University  institutional  review  boards  (Emory 
IRB#22371 and 555–2000, U of C IRB# 16851E, CU IRB#AAAE1819). 
Patient clinical information is detailed in Table I.
PBMC and plasma isolation. All work with samples from infected   
patients was performed in a designated BSL2+ facility at Emory University. 
Peripheral blood mononuclear cells (PBMCs) were isolated using Vacutainer 
tubes (BD), washed, and resuspended in PBS with 2% FCS for immediate use 
or frozen for subsequent analysis. Plasma samples were saved at  80°C or 
frozen in medium with 10% dimethyl sulfoxide for subsequent analysis.
Viruses and antigens. The pandemic H1N1 influenza virus (A/California/ 
04/2009) was provided by R.J. Webby (St. Jude Childrens Hospital, Memphis, 
TN). Influenza virus stocks used for the assays were freshly grown in eggs, 
antibodies bound to past annual viral antigens at lower con-
centrations, suggesting higher avidity to past influenza strains 
than to the current pandemic H1N1 virus. Further, cross- 
reacting cells that bind with higher affinity to the pandemic 
H1N1 strain also have the highest frequency of variable-gene 
mutations (Fig. S3 B). Antibodies that were broadly cross- 
reactive were among the more highly mutated clones (Fig. S3 B). 
We propose that many of these cells were specific for cross-
reactive epitopes present in annual influenza strains that then 
underwent further affinity maturation and adaptation to the 
infecting pandemic H1N1 virus. Supporting this conjecture, 
Corti et al. (2010) first demonstrated that naturally occurring 
HA stalk–reactive memory B cells could be isolated from the 
blood of people recently immunized with the annual vaccine, 
before the outbreak of pandemic H1N1. The nature of that 
study was to screen EBV-transformed memory cell lines, thus 
precluding the determination of precise frequencies of these 
stalk-reactive B cells. However, these antibodies were esti-
mated to be quite rare; occurring at one in thousands to one 
in hundreds of influenza-binding B cells, varying by individ-
ual. In contrast, we show that plasmablasts activated by infec-
tion with the highly novel pandemic H1N1 influenza strain 
have substantially increased targeting to the HA stalk region 
epitopes, totaling 10% of all influenza-specific antibodies and 
half of the neutralizing antibodies (Fig. 4). In fact, most spe-
cific antibodies isolated in this study were cross-reactive to 
past influenza strains. Collectively, the data described supports 
a model in which divergent viruses that are conserved only at 
the most critical regions for function will elicit a higher pro-
portion of cross-reactive and neutralizing antibodies. Thus, 
although the activated plasmablasts of relatively few patients 
could be analyzed in detail at the monoclonal antibody level, 
we proffer that with the proper immunogen, the long-sought 
development of a pan-influenza vaccine might be possible.
Interestingly, the highly specific antibody EM-4C04 was 
derived from a patient that had a very severe disease course, 
with persistent viral shedding over several weeks. In addition, 
the variable genes from the plasmablasts of this patient had the 
lowest average number of somatic mutations (Fig. 2 B, outlier, 
and Fig. S3 B). Collectively, the unique specificity against 
pandemic H1N1, the low levels of somatic mutation, and the 
unusually severe disease in the absence of predisposing condi-
tions suggest that this patient may have mounted a primary 
immune response to the pandemic H1N1 influenza infection. 
The complete lack of preexisting immunity may have con-
tributed to the more severe disease observed in this patient.   
In contrast, the activation of broadly cross-neutralizing mem-
ory B cells in those with immune experience to annual strains 
might have contributed to the less severe disease of most in-
fected patients during the pandemic.
It is notable that there is a discrepancy between patients 
for serum MN titers, the severity of disease, and the frequency 
of plasmablasts expressing neutralizing antibodies (Table I and 
Fig. 3). For example, patient EM, despite having the worst 
disease course, had the greatest HAI and MN serum titers. This 
may be caused by the time from infection (day 31), allowing full JEM VOL. 208, January 17, 2011 
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conditions that were previously published (Wrammert et al., 2008; Smith   
et al., 2009). Variable genes were determined using in-house analysis software 
compared with the Immunogentics V gene dataset and the IMGT search   
engine (Ehrenmann et al., 2010; Lefranc et al., 2009). Background mutation 
rates by this method is 1 base-exchange per 1,000 bases sequenced (based 
on sequences of constant region gene segments). Comparisons were made to 
historical data, some of which was previously published (Zheng et al., 2005; 
Wrammert et al., 2008; Duty et al., 2009).
Plaque assay and PRNT50 assay. MDCK cells were grown in 6-well 
plates at a density of 8 × 105/well. On the next day, cells were washed with 
PBS. 10-fold dilutions of virus were added in 500 µl DME and incubated at 
37°C for 1 h, with mixing every 10 min. Cells were washed with PBS and 
overlayed with 199 media containing 0.5% agarose (Seakem), 1x antibiotics 
(100 U/ml penicillin and 100 mg/ml streptomycin), 0.2% BSA (Sigma- 
Aldrich), and 0.5 µg/ml TPCK-Trypsin (Sigma-Aldrich). Cells were incu-
bated for 36–40 h and fixed with 2% PFA for 10 min. Agarose plugs were 
removed and cells were stained with 0.1% crystal violet in 25% EtOH for   
1 min. After removal from the crystal violet solution, plates were dried and 
used to count plaques in each well. For PRNT50 assay, MDCK cells were pre-
pared as above. On the next day, mAbs were threefold-diluted (60–0.74 µg/ml). 
100 PFU of virus in 250 µl DME were incubated with equal volume of di-
luted mAbs at 37°C for 1 h before the plaque assay. Plaques were counted and 
the final concentration of antibodies that reduced plaques to <50 PFU were 
scored as PRNT50.
Determination  of  50%  tissue  culture  infectious  dose  (TCID50) 
and MN. To determine the TCID50, MDCK cells were grown in 96-well 
plate at a density of 1.5 × 104/well. On the next day, cells were washed with 
PBS and 10-fold diluted viruses in 100 µl DME were added into each well 
and incubated at 37°C for 1 h. After the incubation, cells were washed 
with PBS and 100 µl of DME containing 1x antibiotics (100 U/ml peni-
cillin  and  100  mg/ml  streptomycin),  0.5%  BSA  (Sigma-Aldrich),  and   
0.5 µg/ml TPCK-Trypsin (Sigma-Aldrich) was added. Cells were further   
incubated for 60 h, and 50 µl of the supernatant was incubated with equal 
volume of 0.5% of PBS-washed Turkey red blood cells (Rockland Immu-
nochemicals) for 30 min. Four replicates were performed for each dilu-
tion, and complete agglutination was scored as HA+. Virus titers were 
calculated by the Reed-Muench method. For MN assay, 100 TCID50 of 
virus in 50 µl DME were incubated with 50 µl of threefold-diluted anti-
bodies (60–0.082 µg/ml) at 37°C for 1 h. Cells were washed and incu-
bated in the media as described for the HAI assay for 60 h. The MN titer 
was determined to be the final concentration of mAbs that completely in-
hibited infection.
HAI and ELISA assays. Whole virus, recombinant HA, or vaccine-specific 
ELISA was performed on starting concentrations of 10 µg/ml of virus or re-
combinant HA and on 1:20 dilution of the vaccine, as previously described 
(Wrammert et al., 2008). In brief, microtiter plates were coated with live   
virus strains totaling 8 HAU of total virus per well or with 1 µg/ml of recom-
binant HA protein. To standardize the various ELISA assays, common high-
affinity antibodies with similar affinities and binding characteristics against 
each virus strain were included on each plate, and the plate developed when 
the absorbance of these controls reached 3.0 ± 0.1 OD units. Goat anti–human 
IgG  (goat  anti–human  I-peroxidase-conjugate;  Jackson  ImmunoResearch 
Laboratories) was used to detect binding of the recombinant antibodies, fol-
lowed by development with horseradish peroxidase substrate (Bio-Rad labo-
ratories). Absorbencies were measured at OD415 on a microplate reader 
(Invitrogen). Affinity estimates were calculated by nonlinear regression analy-
sis of curves from eight dilutions of antibody (10 to 0.125 ug/ml) using 
GraphPad Prism. The HAI titers were determined as previously described 
(Wrammert et al., 2008). In brief, the samples were then serially diluted with 
PBS in 96- well v-bottom plates and 8 HAU (as determined by incubation 
with 0.5% turkey RBCs in the absence of serum) of live, egg-grown virus was 
added to the well. After 30 min at room temperature, 50 µl of 0.5% turkey RBCs 
prepared, and purified as previously described (Wrammert et al., 2008).   
The  hemagglutination  inhibition  activity  was  determined  using  turkey 
red blood cells (Lampire Biological Laboratories) as previously described 
(Wrammert et al., 2008) or purchased as inactivated preparations (ProSpec-
Tany TechnoGene Ltd.) which included the following: A/California/04/09 
(H1N1), A/FM/1/47 (H1N1), A/PR8/34 (H1N1), A/New Caledonia/20/99 
(H1N1),  A/Solomon  Island/3/06,  A/Brisbane/59/07  (H1N1),  and   
A/Brisbane/10/07 (H3N2). Vaccines tested included the 2006/7 vaccine 
from Chiron Vaccines Limited and the 2008/9 formulation from Sanofi Pas-
teur Inc. Recombinant HA proteins were provided by the influenza reagent 
resource (www.influenzareagentresource.org) of the CDC (recombinant HA   
from  A/California/04/2009  [H1N1;  #FR-180],  A/Brisbane/10/2007 
[H1N1; #FR-61], A/Brisbane/59/2007 [H3N2; #FR-65]) or by Biodefense 
and Emerging Infections research repository (www.beiresources.org; recom-
binant HA from A/Indonesia/05/2005 [H5N1]). A/Brevig Mission/1/1918 
(H1N1) was purchased from Sino Biological.
ELISPOT assay. Direct ELISPOT to enumerate the number of either total 
IgG-secreting, pandemic H1N1 influenza–specific, or vaccine-specific plasma-
blasts present in the PBMC samples were essentially done as previously 
described (Crotty et al., 2003). In brief, 96-well ELISPOT filter plates (Milli-
pore) were coated overnight with either the optimized amounts of purified 
pandemic H1N1 virions, recombinant HA from the pandemic H1N1 (as 
above), the 08/09 influenza vaccine at a dilution of 1/20 in PBS, or goat 
anti–human Ig (Invitrogen). Plates were washed and blocked by incubation 
with RPMI containing 10% FCS at 37°C for 2 h. Purified and extensively 
washed PBMCs or sorted plasmablasts were added to the plates in dilution 
series and incubated for 6 h. Plates were washed with PBS, followed by PBS 
containing 0.05% Tween, and then incubated with a biotinylated anti-huIgG () 
antibody (Invitrogen) and incubated for 1.5 h at room temperature. After 
washing, the plates were incubated with an avidin-D-HRP conjugate (Vector 
Laboratories) and, finally, developed using AEC substrate (3 amino-9 ethyl-
carbazole; Sigma-Aldrich). Developed plates were scanned and analyzed   
using an automated ELISPOT counter (Cellular Technologies, Ltd.).
Flow cytometry analysis and cell sorting. Analytical flow cytometry 
analysis was performed on whole blood after lysis of erythrocytes and fixing 
in 2% PFA. All live cell sorting and single cell sorting was performed on puri-
fied PBMCs using either a FACSVantage or ARIAII cell sorter system. All of 
the following antibodies for both analytical and cell sorting cytometry were 
purchased from BD, except anti-CD27, which was purchased from eBioscience: 
anti–CD3-PECy7 or PerCP, anti–CD20-PECy7 or PerCP, anti–CD38-PE,   
anti–CD27-APC, and anti–CD19-FITC. ASCs were gated and isolated as 
CD19+CD3CD20lo/CD27high CD38high cells. Flow cytometry data were 
analyzed using FlowJo software.
Generation  of  mAbs. Identification of antibody variable region genes 
were done essentially as previously described (Smith et al., 2009; Wardemann 
et al., 2003; Wrammert et al., 2008). In brief, single ASCs were sorted into 
96-well  PCR  plates  containing  RNase  inhibitor  (Promega). VH  and V 
genes from each cell were amplified by RT-PCR and nested PCR reactions 
using cocktails of primers specific for both IgG and IgA using primer sets 
detailed in (Smith et al., 2009) and then sequenced. To generate recombinant 
antibodies, restriction sites were incorporated by PCR with primers to the par-
ticular variable and junctional genes. VH or V genes amplified from each single 
cell were cloned into IgG1 or Ig expression vectors, as previously described 
(Wardemann et al., 2003; Wrammert et al., 2008; Smith et al., 2009). Antibody 
sequences are deposited on GenBank (accession nos. HQ689701-HQ689792 
available from GenBank/EMBL/DDBJ). Heavy/light chain plasmids were 
cotransfected into the 293A cell line for expression and antibodies purified 
with protein a sepharose. Antibody proteins generated in this study can be 
provided in limited quantities upon request.
Mutational  analysis. Antibody anti-H1N1 induced plasmablast variable 
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efficacy of the mAb, mice were treated intraperitoneally with 200 µg (10 mg/kg 
of body weight) of the specific mAbs. 12 h later, mice were challenged 
with 3xLD50 of one of the mouse adapted influenza viruses used in the 
study. All mice were monitored daily for any signs of morbidity and mor-
tality. Body weight changes were registered daily for a period of 14 d. All 
mice that lost >25% of their initial body weight were sacrificed according 
to the institutional animal care and use committee guidelines. To determine 
the therapeutic efficacy of the mAbs, mice were challenged with 3xLD50 
of the mouse-adapted pandemic H1N1 virus. At various times after infec-
tion (12, 24, 36, 48, 60, and 72 h) mice were treated intraperitoneally with 
200 µg (10 mg/kg of body weight) of the specific mAbs. All mice were 
monitored daily and the body weight changes were registered daily as de-
scribed above.
Statistical analysis. Data were collected and graphed using MS Excel and 
GraphPad Prism software. Efficacy of the therapeutic and challenge experi-
ments was evaluated by analysis of variance using GraphPad Prism software.
Online supplemental material. Fig. S1 shows the binding characteris-
tics of control mAbs. Fig. S2 shows further binding characteristics of the 
neutralizing mAbs. Fig. S3 shows further analysis of pandemic H1N1-induced 
plasmablast somatic mutations. Fig. S4 shows experiments demonstrating   
the therapeutic control of pandemic H1N1 viral titers in lungs after mAb 
treatment. Tables S1–S3 provide detailed characteristics concerning the 
variable gene sequences cloned from pandemic H1N1 induced plasmablasts. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20101352/DC1.
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(Rockland Immunochemicals) suspended in PBS with 0.5% BSA was added to 
each well and the plates were shaken manually. After an additional 30 min at 
room temperature, the serum titers or minimum effective concentrations were 
read based on the final dilution for which a button was observed.
Competition ELISA. Competition ELISA was performed by inhibiting 
binding of each biotinylated antibody (NHS-coupled; Thermo Fisher Scien-
tific) at the half-maximal binding concentration with a 10-fold molar excess 
of purified antibody. All comparisons of different antibodies were based on 
percentage of absorbance values for each antibody against itself (which was 
scored as 100% inhibition). Detection was done using streptavidin-HRP as 
described for the ELISA assay.
FACS analysis of binding of anti-HA antibodies with H5 and its 
mutants. The full-length HA gene (H5-TH04) of A/Thailand/2(SP-33)/2004 
(H5N1) were codon-optimized for eukaryotic cell expression and cloned 
into pcDNA3.1 vector to obtain the pcDNA3.1-H5-TH04 construct (Sui   
et  al.,  2009). All  mutants  of  H5-TH04  were  derived  from  pcDNA3. 
1-H5-TH04 and constructed by the QuikChange method (Stratagene). The 
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